Renaissance Technologies’s BioLineRX BLRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-2,468
Closed -$157K 3681
2023
Q2
$157K Sell
2,468
-184
-7% -$10.2K ﹤0.01% 3350
2023
Q1
$94K Sell
2,652
-3,796
-59% -$99.8K ﹤0.01% 3508
2022
Q4
$152K Buy
6,448
+4,742
+278% +$141K ﹤0.01% 3502
2022
Q3
$63K Buy
1,706
+562
+49% +$32.1K ﹤0.01% 3702
2022
Q2
$59K Sell
1,144
-540
-32% -$30K ﹤0.01% 3965
2022
Q1
$115K Buy
1,684
+1,331
+377% +$92.7K ﹤0.01% 3768
2021
Q4
$29K Sell
353
-72
-17% -$7.51K ﹤0.01% 3823
2021
Q3
$47K Sell
425
-1,520
-78% -$180K ﹤0.01% 3376
2021
Q2
$219K Sell
1,945
-10,683
-85% -$1.26M ﹤0.01% 3228
2021
Q1
$1.41M Buy
12,628
+5,953
+89% +$716K ﹤0.01% 2433
2020
Q4
$673K Sell
6,675
-7
-0.1% -$612 ﹤0.01% 2690
2020
Q3
$438K Buy
6,682
+2,748
+70% +$208K ﹤0.01% 2862
2020
Q2
$269K Buy
+3,934
New +$269K ﹤0.01% 3078
2019
Q1
Sell
-102
Closed -$27K 3455
2018
Q4
$27K Buy
+102
New +$49.1K ﹤0.01% 3314
2018
Q2
Sell
-374
Closed -$195K 3264
2018
Q1
$195K Sell
374
-351
-48% -$215K ﹤0.01% 3182
2017
Q4
$474K Buy
725
+275
+61% +$181K ﹤0.01% 2901
2017
Q3
$303K Buy
+450
New +$280K ﹤0.01% 2898
2017
Q2
Sell
-219
Closed -$126K 3192
2017
Q1
$126K Buy
+219
New +$141K ﹤0.01% 3053
2015
Q1
Sell
-45
Closed -$44K 3162
2014
Q4
$44K Sell
45
-169
-79% -$147K ﹤0.01% 2884
2014
Q3
$197K Buy
214
+141
+193% +$151K ﹤0.01% 2555
2014
Q2
$91K Buy
73
+28
+62% +$35K ﹤0.01% 2675
2014
Q1
$60K Buy
45
+28
+165% +$46K ﹤0.01% 2748
2013
Q4
$29K Sell
17
-86
-83% -$139K ﹤0.01% 2806
2013
Q3
$135K Buy
103
+53
+106% +$62.6K ﹤0.01% 2651
2013
Q2
$48K Buy
+50
New +$51.8K ﹤0.01% 2699

Other funds holding BLRX

Renaissance Technologies's BLRX Position: Q3 2023 in Review

Renaissance Technologies sold out of BioLineRX (BLRX) in Q3 2023, closing a stake of 2,468 shares — an estimated $157K sold.

Renaissance Technologies first reported a position in BLRX in Q2 2013 and held it in 25 quarters. The position peaked at $1.41M in Q1 2021. 29 funds tracked by Wall St. Rank hold BLRX as of Q3 2023.

  • Renaissance Technologies reported no remaining BioLineRX position as of Q3 2023 after selling out during the quarter.
  • Renaissance Technologies sold 2,468 BioLineRX shares in Q3 2023, an estimated $157K.
  • Renaissance Technologies first reported a position in BioLineRX in Q2 2013 and held it in 25 quarters.
  • Renaissance Technologies's BioLineRX position peaked at $1.41M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held BioLineRX as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.